Tilray Medical Expands Australian Cannabis Portfolio with New Redecan, Good Supply Lines
Tilray Medical has launched its largest medical cannabis portfolio expansion in Australia, introducing Redecan flower, extracts, vapes and pastilles alongside Good Supply high-potency flower offerings. The move scales EU-GMP certified supply through local prescriber, pharmacy and clinical channels to meet rising regulated system demand.
1. Portfolio Expansion
Tilray Medical’s expansion in Australia is its largest to date, adding multiple new medical cannabis formats under its Redecan and Good Supply brands. The rollout includes flower, extracts, vapes and pastilles to broaden treatment options for healthcare professionals and patients.
2. Distribution Channels
All products are EU-GMP certified and will be distributed through established prescriber networks, pharmacies and clinical channels. This ensures compliance with Australia’s regulated medical cannabis system and reinforces supply reliability.
3. Strategic Market Commitment
Australia is a key strategic market in Tilray’s international growth plan, supported by rising demand in the country’s regulated system. The expansion underscores Tilray Medical’s long-term investment in local infrastructure and product stewardship.
4. Product Portfolio Details
The Redecan line introduces diversified formats including high-quality flower, extracts, vapes and pastilles, while Good Supply focuses on high-potency flower offerings. These additions aim to meet varying patient needs and support differentiated treatment protocols.